Literature DB >> 9792377

Persistence of Pseudomonas aeruginosa strains in respiratory infection in AIDS patients.

D Asboe1, V Gant, H M Aucken, D A Moore, S Umasankar, J S Bingham, M E Kaufmann, T L Pitt.   

Abstract

OBJECTIVES: To establish the clinical pattern of Pseudomonas aeruginosa respiratory infections in HIV-seropositive patients and to determine whether repeated isolation of the organism represents reinfection or recurrence and to assess whether common source, nosocomial infection occurred. DESIGN AND METHODS: Evaluation of the clinical pattern of P. aeruginosa respiratory infections by case note review and epidemiological characterization of P. aeruginosa by serotype determination and Xbal DNA macrorestriction analysis. Serum sensitivity testing of strains was performed to further define phenotypic characteristics of the isolated organisms.
RESULTS: Seventy-three per cent (29 out of 40) of individuals had P. aeruginosa isolated on two or more occasions in the setting of clinical respiratory infection. Overall, 85% had evidence of P. aeruginosa to within 2 months of study completion or death. Epidemiological characterization revealed persistence of unique single strains in 93% of individuals where multiple isolates were available for testing, whereas only two patients harboured a common strain. The serotype distribution of strains was similar to that reported from non-HIV-positive patients.
CONCLUSIONS: Once established, eradication of P. aeruginosa from the respiratory tract of HIV-seropositive individuals with advanced immunosuppression is problematic and a chronic infective state appears common. There was no evidence of nosocomial transmission. Serotype loss and development of sensitivity to normal human serum were both observed and were highly correlated. This represents truncation of O-antigenic lipopolysaccharide on the cell surface of P. aeruginosa and may reflect progression to phenotypes commonly associated with chronic infection in other clinical settings such as cystic fibrosis.

Entities:  

Mesh:

Year:  1998        PMID: 9792377     DOI: 10.1097/00002030-199814000-00008

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  8 in total

1.  The sexual health of adolescents with cystic fibrosis.

Authors:  Stephen Roberts; Pippa Green
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

2.  Simple and inexpensive but highly discriminating method for computer-assisted DNA fingerprinting of Pseudomonas aeruginosa.

Authors:  T H Al-Samarrai; N Zhang; I L Lamont; L Martin; J Kolbe; M Wilsher; A J Morris; J Schmid
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

3.  Growth phase-dependent invasion of Pseudomonas aeruginosa and its survival within HeLa cells.

Authors:  U Ha; S Jin
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

4.  Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1.

Authors:  Diansy Zincke; Deepak Balasubramanian; Lynn L Silver; Kalai Mathee
Journal:  Antimicrob Agents Chemother       Date:  2015-11-30       Impact factor: 5.191

Review 5.  Genetics of O-antigen biosynthesis in Pseudomonas aeruginosa.

Authors:  H L Rocchetta; L L Burrows; J S Lam
Journal:  Microbiol Mol Biol Rev       Date:  1999-09       Impact factor: 11.056

6.  DsbA of Pseudomonas aeruginosa is essential for multiple virulence factors.

Authors:  Un-Hwan Ha; Yanping Wang; Shouguang Jin
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

7.  Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.

Authors:  Irma A J M Bakker-Woudenberg; Marian T ten Kate; Luke Guo; Peter Working; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Regulation of Virus-Associated Lymphoma Growth and Gene Expression by Bacterial Quorum-Sensing Molecules.

Authors:  Jing Qiao; Yueyu Cao; Jovanny Zabaleta; Liang Yang; Lu Dai; Zhiqiang Qin
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.